{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:25:15Z","timestamp":1781720715130,"version":"3.54.5"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11916-026-01485-5","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:33:49Z","timestamp":1777361629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The OPRM1 A118G Polymorphism Revisited: Recent Developments and Implications for Personalized Treatment"],"prefix":"10.1007","volume":"30","author":[{"given":"Isaac","family":"Daybell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Wie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooks","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Covington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Pew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"1485_CR1","doi-asserted-by":"publisher","first-page":"e0277427","DOI":"10.1371\/journal.pone.0277427","volume":"17","author":"J Tour","year":"2022","unstructured":"Tour J, Sandstr\u00f6m A, Kadetoff D, Schalling M, Kosek E. The OPRM1 gene and interactions with the 5-HT1a gene regulate conditioned pain modulation in fibromyalgia patients and healthy controls. PLoS ONE. 2022;17:e0277427.","journal-title":"PLoS ONE"},{"key":"1485_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1471-4159.2007.04738.x","volume":"103","author":"T Kroslak","year":"2007","unstructured":"Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem. 2007;103:77\u201387.","journal-title":"J Neurochem"},{"key":"1485_CR3","doi-asserted-by":"publisher","first-page":"32618","DOI":"10.1074\/jbc.M504942200","volume":"280","author":"Y Zhang","year":"2005","unstructured":"Zhang Y, Wang D, Johnson AD, Papp AC, Sad\u00e9e W. Allelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G. J Biol Chem. 2005;280:32618\u201324.","journal-title":"J Biol Chem"},{"key":"1485_CR4","doi-asserted-by":"publisher","first-page":"9608","DOI":"10.1073\/pnas.95.16.9608","volume":"95","author":"C Bond","year":"1998","unstructured":"Bond C, Laforge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters \u03b2-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci. 1998;95:9608\u201313.","journal-title":"Proc Natl Acad Sci"},{"key":"1485_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-023-02120-1","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Cao L, Yang Y, Gao Y, Li Y, Wang B, Pan B, Huang J, Guo W. Is OPRM1 genotype a valuable predictor of VAS in patients undergoing laparoscopic radical resection of colorectal cancer with fentanyl? BMC Anesthesiol. 2023. https:\/\/doi.org\/10.1186\/s12871-023-02120-1.","journal-title":"BMC Anesthesiol"},{"key":"1485_CR6","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1038\/npp.2015.101","volume":"40","author":"WR Lovallo","year":"2015","unstructured":"Lovallo WR, Enoch M-A, Acheson A, Cohoon AJ, Sorocco KH, Hodgkinson CA, Vincent AS, Glahn DC, Goldman D. Cortisol Stress Response in Men and Women Modulated Differentially by the Mu-Opioid Receptor Gene Polymorphism OPRM1 A118G. Neuropsychopharmacology. 2015;40:2546\u201354.","journal-title":"Neuropsychopharmacology"},{"key":"1485_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2674","author":"A Suzuki","year":"2022","unstructured":"Suzuki A, Shirata T, Noto K, Matsumoto Y, Muraosa H, Abe M, Goto K, Otani K. Associations of the A118G OPRM1 polymorphism with sociotropy and interpersonal sensitivity. Brain Behav. 2022. https:\/\/doi.org\/10.1002\/brb3.2674.","journal-title":"Brain Behav"},{"key":"1485_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39622-3","author":"B Nobile","year":"2019","unstructured":"Nobile B, Ramoz N, Jaussent I, Gorwood P, Oli\u00e9 E, Castroman JL, Guillaume S, Courtet P. Polymorphism A118G of opioid receptor mu 1 (OPRM1) is associated with emergence of suicidal ideation at antidepressant onset in a large naturalistic cohort of depressed outpatients. Sci Rep. 2019. https:\/\/doi.org\/10.1038\/s41598-019-39622-3.","journal-title":"Sci Rep"},{"issue":"10","key":"1485_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2217\/pgs-2022-0042","volume":"23","author":"Y Liew","year":"2022","unstructured":"Liew Y, Capule FR, Makmor-Bakry M. Genetic polymorphisms of OPRM1 on the efficacy and safety of anesthetic and analgesic agents: a systematic review. Pharmacogenomics. 2022;23(10):609\u201317. https:\/\/doi.org\/10.2217\/pgs-2022-0042.","journal-title":"Pharmacogenomics"},{"key":"1485_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jpainsymman.2023.09.017","volume":"67","author":"M Takemura","year":"2024","unstructured":"Takemura M, Niki K, Okamoto Y, Kawamura T, Kohno M, Matsuda Y, Ikeda K. Comparison of the Effects of OPRM1 A118G Polymorphism Using Different Opioids: A Prospective Study. J Pain Symptom Manag. 2024;67:39\u2013e495.","journal-title":"J Pain Symptom Manag"},{"key":"1485_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cpt.2149","volume":"110","author":"KR Crews","year":"2021","unstructured":"Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110:888\u201396.","journal-title":"Clin Pharmacol Ther"},{"key":"1485_CR12","doi-asserted-by":"publisher","unstructured":"Cao B, Xu Q, Shi Y, Zhao R, Li H, Zheng J, Liu F, Wan Y, Wei B. Pathology of pain and its implications for therapeutic interventions. Signal Transduct Target Therapy. 2024;9(1). https:\/\/doi.org\/10.1038\/s41392-024-01845-w.","DOI":"10.1038\/s41392-024-01845-w"},{"key":"1485_CR13","doi-asserted-by":"crossref","unstructured":"Mura E, Govoni, Racchi, Carossa, Ranzani, Allegri M, Van Schaik. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Res. 2013; 331","DOI":"10.2147\/JPR.S42040"},{"key":"1485_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/ejp.1680","volume":"25","author":"I Ellerbrock","year":"2021","unstructured":"Ellerbrock I, Sandstr\u00f6m A, Tour J, Kadetoff D, Schalling M, Jensen KB, Kosek E. Polymorphisms of the \u00b5-opioid receptor gene influence cerebral pain processing in fibromyalgia. Eur J Pain. 2021;25:398\u2013414.","journal-title":"Eur J Pain"},{"issue":"4","key":"1485_CR15","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1007\/s11682-022-00652-7","volume":"16","author":"T Li","year":"2022","unstructured":"Li T, Zhang S, Ikeda E, Kobinata H. Functional connectivity modulations during offset analgesia in chronic pain patients: an fMRI study. Brain Imaging Behav. 2022;16(4):1794\u2013802. https:\/\/doi.org\/10.1007\/s11682-022-00652-7.","journal-title":"Brain Imaging Behav"},{"key":"1485_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/npp.2014.272","volume":"40","author":"M Peci\u00f1a","year":"2015","unstructured":"Peci\u00f1a M, Love T, Stohler CS, Goldman D, Zubieta J-K. Effects of the Mu Opioid Receptor Polymorphism (OPRM1 A118G) on Pain Regulation, Placebo Effects and Associated Personality Trait Measures. Neuropsychopharmacology. 2015;40:957\u201365.","journal-title":"Neuropsychopharmacology"},{"key":"1485_CR17","doi-asserted-by":"publisher","first-page":"6530","DOI":"10.1074\/jbc.M807030200","volume":"284","author":"BG Oertel","year":"2009","unstructured":"Oertel BG, Kettner M, Scholich K, Renn\u00e9 C, Roskam B, Geisslinger G, Schmidt PH, L\u00f6tsch J. A Common Human \u00b5-Opioid Receptor Genetic Variant Diminishes the Receptor Signaling Efficacy in Brain Regions Processing the Sensory Information of Pain. J Biol Chem. 2009;284:6530\u20135.","journal-title":"J Biol Chem"},{"key":"1485_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2217\/pgs.10.47","volume":"11","author":"UM Stamer","year":"2010","unstructured":"Stamer UM, Zhang L, St\u00fcber F. Personalized Therapy in Pain Management: Where Do We Stand? Pharmacogenomics. 2010;11:843\u201364.","journal-title":"Pharmacogenomics"},{"issue":"5","key":"1485_CR19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.pain.2011.01.040","volume":"152","author":"P Klepstad","year":"2011","unstructured":"Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, Davies A, Kloke M, Lundstr\u00f6m S, Maltoni M, Radbruch L, Sabatowski R, Sigurdardottir V, Strasser F, Fayers PM, Kaasa S, European Palliative Care Research Collaborative (EPCRC) and the European Association for Palliative Care Research Network. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain. 2011;152(5):1139\u201345. https:\/\/doi.org\/10.1016\/j.pain.2011.01.040.","journal-title":"Pain"},{"key":"1485_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-024-00339-w","author":"DT Barratt","year":"2024","unstructured":"Barratt DT, Klepstad P, Dale O, Kaasa S, Somogyi AA. Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects. Pharmacogenomics J. 2024. https:\/\/doi.org\/10.1038\/s41397-024-00339-w.","journal-title":"Pharmacogenomics J"},{"key":"1485_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/bcpt.13155","volume":"124","author":"J Muriel","year":"2019","unstructured":"Muriel J, Margarit C, Barrachina J, Ballester P, Flor A, Morales D, Horga JF, Fern\u00e1ndez E. Ana Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients. Basic Clin Pharmacol Toxicol. 2019;124:439\u201348.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1485_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3346\/jkms.2015.30.5.651","volume":"30","author":"S-H Lee","year":"2015","unstructured":"Lee S-H, Kim J-D, Park S-A, Oh C-S, Kim S-H. Effects of \u00b5-Opioid Receptor Gene Polymorphism on Postoperative Nausea and Vomiting in Patients Undergoing General Anesthesia with Remifentanil: Double Blinded Randomized Trial. J Korean Med Sci. 2015;30:651.","journal-title":"J Korean Med Sci"},{"issue":"9","key":"1485_CR23","first-page":"2764","volume":"10","author":"Y Kong","year":"2018","unstructured":"Kong Y, Yan T, Gong S, Deng H, Zhang G, Wang J. Opioid receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) and postoperative nausea and vomiting. Am J Transl Res. 2018;10(9):2764\u201380.","journal-title":"Am J Transl Res"},{"key":"1485_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/tpj.2014.59","volume":"15","author":"V Chidambaran","year":"2015","unstructured":"Chidambaran V, Mavi J, Esslinger H, Pilipenko V, Martin LJ, Zhang K, Sadhasivam S. Association of OPRM1 A118G variant with risk of morphine-induced respiratory depression following spine fusion in adolescents. Pharmacogenomics J. 2015;15:255\u201362.","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"1485_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/00000542-200503000-00008","volume":"102","author":"RR Romberg","year":"2005","unstructured":"Romberg RR, Olofsen E, Bijl H, Taschner PE, Teppema LJ, Sarton EY, van Kleef JW, Dahan A. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A\u2009>\u2009G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology. 2005;102(3):522\u201330. https:\/\/doi.org\/10.1097\/00000542-200503000-00008.","journal-title":"Anesthesiology"},{"key":"1485_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2478\/raon-2023-0003","volume":"57","author":"Z Vidic","year":"2023","unstructured":"Vidic Z, Goricar K, Strazisar B, Besic N, Dolzan V. Association of OPRM1, MIR23B, and MIR107 genetic variability with acute pain, chronic pain and adverse effects after postoperative tramadol and paracetamol treatment in breast cancer. Radiol Oncol. 2023;57:111\u201320.","journal-title":"Radiol Oncol"},{"issue":"6","key":"1485_CR27","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1038\/ctg.2015.19","volume":"6","author":"EA Laugsand","year":"2015","unstructured":"Laugsand EA, Skorpen F, Kaasa S, Sabatowski R, Strasser F, Fayers P, Klepstad P. Genetic and non-genetic factors associated with constipation in cancer patients receiving opioids. Clin Transl Gastroenterol. 2015;6(6):e90. https:\/\/doi.org\/10.1038\/ctg.2015.19.","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"1485_CR28","first-page":"E227","volume":"16","author":"MV Boswell","year":"2013","unstructured":"Boswell MV, Stauble ME, Loyd GE, Langman L, Ramey-Hartung B, Baumgartner RN, Tucker WW, Jortani SA. The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone. Pain Physician. 2013;16(3):E227\u201335.","journal-title":"Pain Physician"},{"issue":"44","key":"1485_CR29","doi-asserted-by":"publisher","first-page":"e27565","DOI":"10.1097\/MD.0000000000027565","volume":"5","author":"R Tanaka","year":"2021","unstructured":"Tanaka R, Sato J, Ishikawa H, Sato T, Shino M, Ohde Y, Sato T, Mori K, Notsu A, Ohnami S, Mizuguchi M, Nagashima T, Yamaguchi K. Influence of genetic variants of opioid-related genes on opioid-induced adverse effects in patients with lung cancer: A STROBE-compliant observational study. Med (Baltim). 2021;5(44):e27565. https:\/\/doi.org\/10.1097\/MD.0000000000027565.","journal-title":"Med (Baltim)"},{"issue":"1","key":"1485_CR30","first-page":"97","volume":"22","author":"C Margarit","year":"2019","unstructured":"Margarit C, Ballester P, Inda MD, Roca R, Gomez L, Planelles B, Ajo R, Morales D, Peir\u00f3 AM. OPRM1 gene interaction with sleep in chronic pain patients treated with opioids. Pain Physician. 2019;22(1):97\u2013107.","journal-title":"Pain Physician"},{"issue":"10","key":"1485_CR31","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1001\/jamapsychiatry.2020.1206","volume":"77","author":"H Zhou","year":"2020","unstructured":"Zhou H, Rentsch CT, Cheng Z, Kember RL, Nunez YZ, Sherva RM, et al. Association of OPRM1 functional coding variant with opioid use disorder: a genome-wide association study. JAMA Psychiatry. 2020;77(10):1072\u201380. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.1206.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"1485_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-21003-y","volume":"12","author":"N Gaddis","year":"2022","unstructured":"Gaddis N, Mathur R, Marks J, Zhou L, Quach B, Waldrop A, et al. Multi-trait genome-wide association study of opioid addiction: OPRM1 and beyond. Sci Rep. 2022;12(1):1\u201316.","journal-title":"Sci Rep"},{"issue":"3","key":"1485_CR33","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s44220-023-00034-y","volume":"1","author":"AS Hatoum","year":"2023","unstructured":"Hatoum AS, Colbert SMC, Johnson EC, Huggett SB, Deak JD, Pathak G, Jennings MV, Substance Use Disorder Working Group of the Psychiatric Genomics Consortium, et al. Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders. Nat Ment Health. 2023;1(3):210\u201323. https:\/\/doi.org\/10.1038\/s44220-023-00034-y.","journal-title":"Nat Ment Health"},{"issue":"1","key":"1485_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/adb.13355","volume":"29","author":"KE Dunn","year":"2024","unstructured":"Dunn KE, Huhn AS, Finan PH, Mange A, Bergeria CL, Maher BS, et al. Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype\u2013genotype assessment. Addict Biol. 2024;29(1):1\u201311.","journal-title":"Addict Biol"},{"issue":"5","key":"1485_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/npp.2014.286","volume":"40","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Picetti R, Butelman ER, Ho A, Blendy JA, Kreek MJ. Mouse Model of the OPRM1 (A118G) Polymorphism: Differential Heroin Self-Administration Behavior Compared with Wild-Type Mice. Neuropsychopharmacology. 2015;40(5):1091\u2013100. https:\/\/doi.org\/10.1038\/npp.2014.286.","journal-title":"Neuropsychopharmacology"},{"issue":"29","key":"1485_CR36","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.1523\/JNEUROSCI.2317-18.2019","volume":"39","author":"D Popova","year":"2019","unstructured":"Popova D, Desai N, Blendy JA, Pang ZP. Synaptic Regulation by OPRM1 Variants in Reward Neurocircuitry. J Neurosci. 2019;39(29):5685\u201396.","journal-title":"J Neurosci"},{"issue":"2","key":"1485_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1601-183X.2010.00655.x","volume":"10","author":"AM Dlugos","year":"2011","unstructured":"Dlugos AM, Hamidovic A, Hodgkinson C, Shen PH, Goldman D, Palmer AA, et al. OPRM1 gene variants modulate amphetamine-induced euphoria in humans. Genes Brain Behav. 2011;10(2):199\u2013209.","journal-title":"Genes Brain Behav"},{"issue":"10","key":"1485_CR38","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2217\/pgs.12.99","volume":"13","author":"E Setiawan","year":"2012","unstructured":"Setiawan E, Pihl RO, Benkelfat C, Leyton M. Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. Pharmacogenomics. 2012;13(10):1161\u201372.","journal-title":"Pharmacogenomics"},{"issue":"5","key":"1485_CR39","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1177\/0269881121991992","volume":"35","author":"M Sebold","year":"2021","unstructured":"Sebold M, Garbusow M, Cerci D, Chen K, Sommer C, Huys QJ, et al. Association of the OPRM1 A118G polymorphism and Pavlovian-to-instrumental transfer: Clinical relevance for alcohol dependence. J Psychopharmacol. 2021;35(5):566\u201378.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1485_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12881-017-0478-4","volume":"18","author":"X Kong","year":"2017","unstructured":"Kong X, Deng H, Gong S, Alston T, Kong Y, Wang J. Lack of associations of the opioid receptor mu 1 (OPRM1) A118G polymorphism (rs1799971) with alcohol dependence: review and meta-analysis of retrospective controlled studies. BMC Med Genet. 2017;18(1):1\u201313.","journal-title":"BMC Med Genet"},{"issue":"3 Suppl","key":"1485_CR41","doi-asserted-by":"publisher","first-page":"ES67","DOI":"10.1016\/j.pain.2012.04.022","volume":"15","author":"N Sehgal","year":"2012","unstructured":"Sehgal N, Manchikanti L, Smith HS. Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse. Pain Physician. 2012;15(3 Suppl):ES67\u201392. https:\/\/doi.org\/10.1016\/j.pain.2012.04.022.","journal-title":"Pain Physician"},{"issue":"3","key":"1485_CR42","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cpt.3112","volume":"115","author":"I Kazi","year":"2024","unstructured":"Kazi I, Chenoweth MJ, Jutras-Aswad D, Ahamad K, Socias ME, Le Foll B, et al. Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine\/Naloxone. Clin Pharmacol Ther. 2024;115(3):506\u201314.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1485_CR43","doi-asserted-by":"publisher","first-page":"626","DOI":"10.5414\/CP203755","volume":"58","author":"H Imai","year":"2020","unstructured":"Imai H, Morita M, Morita H, Ohyama T, Tanaka S, Uchida S, Namiki N, Uemura N, Ohashi K. The \u00b5-opioid receptor gene polymorphism 118A\u2009>\u2009G weakens the pharmacological action of buprenorphine. Int J Clin Pharmacol Ther. 2020;58(11):626\u201333. https:\/\/doi.org\/10.5414\/CP203755.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"1485_CR44","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/00952990.2020.1797064","volume":"46","author":"M Randesi","year":"2020","unstructured":"Randesi M, Rotrosen J, Nunes EV, Lee JD, Novo P, Levran O, et al. Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians. Am J Drug Alcohol Abus. 2020;46(6):761\u20138.","journal-title":"Am J Drug Alcohol Abus"},{"issue":"1","key":"1485_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/ajad.12172","volume":"24","author":"IE Bauer","year":"2015","unstructured":"Bauer IE, Soares JC, Nielsen DA. The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review. Am J Addictions. 2015;24(1):15\u201323.","journal-title":"Am J Addictions"},{"key":"1485_CR46","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2147\/JPR.S442431","volume":"17","author":"E Trimble","year":"2024","unstructured":"Trimble E, Kell P, Avella M, France C, Rhudy J. Opioid Receptor Mu 1 Gene (OPRM1) A118G Polymorphism and Emotional Modulation of Pain. J Pain Res. 2024;17:489\u2013500.","journal-title":"J Pain Res"},{"issue":"12","key":"1485_CR47","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1038\/s41380-019-0429-5","volume":"25","author":"Z Jiang","year":"2020","unstructured":"Jiang Z, Zhang L, Zhao J, Chen Z, Zhang L, Zhen Z, et al. Influence of the OPRM1 gene polymorphism upon children\u2019s degree of withdrawal and brain reactivity to facial expressions. Mol Psychiatry. 2020;25(12):3004\u201312. https:\/\/doi.org\/10.1038\/s41380-019-0429-5.","journal-title":"Mol Psychiatry"},{"issue":"7","key":"1485_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/brb3.1659","volume":"10","author":"S Cimino","year":"2020","unstructured":"Cimino S, Carola V, Cerniglia L, Bussone S, Bevilacqua A, Tambelli R. The \u00b5-opioid receptor gene A118G polymorphism is associated with insecure attachment in children with disruptive mood regulation disorder and their mothers. Brain Behav. 2020;10(7):1\u201312.","journal-title":"Brain Behav"},{"issue":"1","key":"1485_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-78783-4","volume":"10","author":"AM Daniel","year":"2020","unstructured":"Daniel AM, Rushing BG, Tapia Menchaca KY. Variation of the human mu-opioid receptor (OPRM1) gene predicts vulnerability to frustration. Sci Rep. 2020;10(1):1\u20138.","journal-title":"Sci Rep"},{"key":"1485_CR50","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.psyneuen.2014.07.009","volume":"49","author":"GM Slavich","year":"2014","unstructured":"Slavich GM, Tartter MA, Brennan PA, Hammen C. Endogenous opioid system influences depressive reactions to socially painful targeted rejection life events. Psychoneuroendocrinology. 2014;49:141\u20139.","journal-title":"Psychoneuroendocrinology"},{"issue":"11","key":"1485_CR51","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/jclp.20322","volume":"62","author":"CO Townsend","year":"2006","unstructured":"Townsend CO, Bruce BK, Hooten WM, Rome JD. The role of mental health professionals in multidisciplinary pain rehabilitation programs. J Clin Psychol. 2006;62(11):1433\u201343. https:\/\/doi.org\/10.1002\/jclp.20322.","journal-title":"J Clin Psychol"},{"issue":"12","key":"1485_CR52","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/pm\/pnw317","volume":"18","author":"RA Lloyd","year":"2017","unstructured":"Lloyd RA, Hotham E, Hall C, Williams M, Suppiah V. Pharmacogenomics and patient treatment parameters to opioid treatment in chronic pain: A focus on morphine, oxycodone, tramadol, and fentanyl. Pain Med. 2017;18(12):2369\u201387. https:\/\/doi.org\/10.1093\/pm\/pnw317.","journal-title":"Pain Med"},{"issue":"10","key":"1485_CR53","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s11864-022-01010-x","volume":"23","author":"AK Wong","year":"2022","unstructured":"Wong AK, Somogyi AA, Rubio J, Philip J. The Role of Pharmacogenomics in Opioid Prescribing. Curr Treat Options Oncol. 2022;23(10):1353\u201369.","journal-title":"Curr Treat Options Oncol"},{"issue":"13","key":"1485_CR54","doi-asserted-by":"publisher","first-page":"10754","DOI":"10.3390\/ijms241310754","volume":"24","author":"L Agull\u00f3","year":"2023","unstructured":"Agull\u00f3 L, Aguado I, Muriel J, Margarit C, G\u00f3mez A, Escorial M, et al. Pharmacogenetic Guided Opioid Therapy Improves Chronic Pain Outcomes and Comorbid Mental Health: A Randomized, Double-Blind, Controlled Study. Int J Mol Sci. 2023;24(13):10754.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1485_CR55","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3390\/cancers12071951","volume":"12","author":"D Bugada","year":"2020","unstructured":"Bugada D, Lorini LF, Fumagalli R, Allegri M. Genetics and Opioids: Towards More Appropriate Prescription in Cancer Pain. Cancers. 2020;12(7):1951.","journal-title":"Cancers"},{"key":"1485_CR56","doi-asserted-by":"crossref","unstructured":"Spampinato SM. Overview of genetic analysis of human opioid receptors. Methods Mol Biol. 2021;2201:3\u201313.","DOI":"10.1007\/978-1-0716-0884-5_1"},{"issue":"6","key":"1485_CR57","doi-asserted-by":"publisher","first-page":"611","DOI":"10.36076\/ppj.2018.6.E611","volume":"21","author":"G Ruano","year":"2018","unstructured":"Ruano G, Kost JA. Fundamental considerations for genetically-guided pain management with opioids based on CYP2D6 and OPRM1 polymorphisms. Pain Physician. 2018;21(6):611\u201321.","journal-title":"Pain Physician"},{"key":"1485_CR58","doi-asserted-by":"publisher","first-page":"112060","DOI":"10.1016\/j.biopha.2021.112060","volume":"142","author":"L Magarbeh","year":"2021","unstructured":"Magarbeh L, Gorbovskaya I, Le Foll B, Jhirad R, M\u00fcller DJ. Reviewing pharmacogenetics to advance precision medicine for opioids. Biomed Pharmacother. 2021;142:112060. https:\/\/doi.org\/10.1016\/j.biopha.2021.112060.","journal-title":"Biomed Pharmacother"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01485-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-026-01485-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-026-01485-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T07:33:57Z","timestamp":1777361637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-026-01485-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1485"],"URL":"https:\/\/doi.org\/10.1007\/s11916-026-01485-5","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"58"}}